In-silico development of a novel TLR2-mediating multi-epitope vaccine against <i>Mycobacterium tuberculosis</i>.

ABSTRACT: Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), still remains one of the leading causes of mortality worldwide. The elusive nature of this pathogen and its ability to develop drug resistance makes it a serious threat to global health. BCG, the only preventive vaccine for TB, has a limited efficacy and provides partial protection against the disease. A new effective recombinant vaccine capable of producing a stronger and more comprehensive immune response is required to address this global threat. In the present study, we adopted an in-silico approach to develop a multi-epitope vaccine by screening 198 "regulatory proteins" of Mtb H37Rv strain. Epitopes generated from these proteins were screened on the basis of antigenicity, cytokine profile, allergenicity, toxicity,

SUBMITTER: Singh S 

PROVIDER: S-EPMC11861476 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature